Profile data is unavailable for this security.
About the company
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
- Revenue in GBP (TTM)32.67bn
- Net income in GBP5.72bn
- Incorporated1999
- Employees68.63k
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck KGaA | 18.63bn | 2.59bn | 48.87bn | 62.35k | 18.88 | 1.93 | 11.45 | 2.62 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
| Regeneron Pharmaceuticals Inc | 10.64bn | 3.37bn | 61.28bn | 15.41k | 18.63 | 2.64 | 16.23 | 5.76 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
| Chugai Pharmaceutical Co Ltd | 5.98bn | 2.06bn | 83.42bn | 7.78k | 39.64 | 8.49 | -- | 13.95 | 263.73 | 263.73 | 764.40 | 1,230.91 | 0.5379 | 1.41 | 3.59 | -- | 18.56 | 19.40 | 21.83 | 23.54 | 71.09 | 66.75 | 34.50 | 31.46 | 3.56 | 583.66 | -- | 40.95 | 7.46 | 9.84 | 12.06 | 15.11 | 12.69 | 17.27 |
| Sanofi SA | 40.93bn | 4.33bn | 87.82bn | 76.49k | 20.42 | 1.39 | 14.51 | 2.15 | 4.03 | 6.36 | 38.11 | 59.11 | 0.3599 | 1.33 | 5.81 | 610,722.60 | 3.95 | 4.87 | 5.10 | 6.07 | 72.07 | 70.15 | 10.99 | 14.05 | 0.7316 | 31.31 | 0.2208 | 77.11 | 5.49 | 4.57 | -10.13 | -16.67 | 11.18 | 5.18 |
| GSK plc | 32.67bn | 5.72bn | 89.64bn | 68.63k | 15.83 | 5.48 | 8.90 | 2.74 | 1.39 | 1.39 | 7.95 | 4.02 | 0.5418 | 1.54 | 4.57 | -- | 10.43 | 7.00 | 16.02 | 10.95 | 72.67 | 71.30 | 19.25 | 15.49 | 0.5416 | 16.90 | 0.5262 | 69.37 | 4.11 | 6.05 | 121.98 | 5.07 | 5.92 | -7.97 |
| Vertex Pharmaceuticals Inc | 8.90bn | 2.93bn | 93.59bn | 6.40k | 32.40 | 6.76 | 30.32 | 10.52 | 15.33 | 15.33 | 46.51 | 73.49 | 0.4982 | 1.14 | 6.55 | 1,875,203.00 | 16.41 | 13.29 | 19.40 | 15.74 | 86.24 | 86.99 | 32.94 | 25.71 | 2.46 | -- | 0.0057 | 0.00 | 8.90 | 14.10 | 838.09 | 7.83 | 10.99 | -- |
| Bristol-Myers Squibb Co | 35.74bn | 5.23bn | 94.19bn | 32.50k | 18.03 | 6.80 | 11.48 | 2.64 | 3.46 | 3.46 | 23.64 | 9.18 | 0.5278 | 5.03 | 5.02 | 1,482,892.00 | 7.73 | 3.92 | 10.43 | 5.05 | 72.63 | 76.32 | 14.64 | 8.34 | 1.14 | 16.84 | 0.7091 | 122.54 | -0.2195 | 2.54 | 178.83 | -- | 11.73 | 0.658 |
| Novo Nordisk A/S | 36.24bn | 12.01bn | 94.56bn | 68.79k | 10.33 | 5.45 | 6.51 | 2.61 | 23.03 | 23.03 | 69.49 | 43.66 | 0.6128 | 1.30 | 4.33 | 4,492,601.00 | 20.31 | 25.03 | 35.60 | 48.23 | 80.98 | 83.95 | 33.14 | 33.96 | 0.5696 | -- | 0.4029 | 50.28 | 6.43 | 19.48 | 1.43 | 19.44 | 32.48 | 20.79 |
| Pfizer Inc | 46.40bn | 5.74bn | 116.59bn | 75.00k | 20.40 | 1.82 | 10.93 | 2.51 | 1.36 | 1.36 | 10.97 | 15.21 | 0.2969 | 1.41 | 5.36 | 834,386.70 | 3.69 | 7.19 | 4.57 | 9.08 | 75.81 | 69.03 | 12.44 | 19.52 | 0.8718 | 9.40 | 0.4275 | 64.91 | -1.65 | 8.48 | -3.42 | 3.16 | -1.19 | 2.50 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Feb 2026 | 112.86m | 2.77% |
| Dodge & Coxas of 20 Feb 2025 | 99.38m | 2.44% |
| Schroder Investment Management Ltd.as of 02 Feb 2026 | 67.24m | 1.65% |
| Norges Bank Investment Managementas of 02 Feb 2026 | 65.37m | 1.60% |
| BlackRock Advisors (UK) Ltd.as of 02 Feb 2026 | 64.19m | 1.58% |
| Wellington Management Co. LLPas of 02 Feb 2026 | 63.11m | 1.55% |
| BlackRock Fund Advisorsas of 02 Feb 2026 | 62.26m | 1.53% |
| Legal & General Investment Management Ltd.as of 02 Feb 2026 | 53.96m | 1.32% |
| SSgA Funds Management, Inc.as of 02 Feb 2026 | 51.50m | 1.26% |
| Vanguard Asset Management Ltd.as of 02 Feb 2026 | 48.86m | 1.20% |
